EP 9001A
Alternative Names: EP-9001ALatest Information Update: 28 May 2025
At a glance
- Originator Easton Biopharmaceuticals
- Class Monoclonal antibodies; Non-opioid analgesics
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer pain; Neuropathic pain
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Cancer-pain(In volunteers) in China (SC, Injection)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in China (SC, Injection)
- 18 Apr 2022 Phase-I clinical trials in Cancer pain (In volunteers) in China (SC) (NCT05278611)